BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 22385219)

  • 1. Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin.
    Kreutz RP; Nystrom P; Kreutz Y; Miao J; Kovacs R; Desta Z; Flockhart DA; Jin Y
    Platelets; 2013; 24(2):145-50. PubMed ID: 22385219
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of a new P2Y12 receptor specific platelet aggregation test with other laboratory methods in stroke patients on clopidogrel monotherapy.
    Bagoly Z; Sarkady F; Magyar T; Kappelmayer J; Pongrácz E; Csiba L; Muszbek L
    PLoS One; 2013; 8(7):e69417. PubMed ID: 23844259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
    Malinin A; Pokov A; Spergling M; Defranco A; Schwartz K; Schwartz D; Mahmud E; Atar D; Serebruany V
    Thromb Res; 2007; 119(3):277-84. PubMed ID: 16563469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction analysis between genetic polymorphisms and pharmacodynamic effect in patients treated with adjunctive cilostazol to dual antiplatelet therapy: results of the ACCEL-TRIPLE (Accelerated Platelet Inhibition by Triple Antiplatelet Therapy According to Gene Polymorphism) study.
    Kim IS; Jeong YH; Park Y; Yoon SE; Kwon TJ; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
    Br J Clin Pharmacol; 2012 Apr; 73(4):629-40. PubMed ID: 22007612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Platelet inhibition by adjunctive cilostazol versus high maintenance-dose clopidogrel in patients with acute myocardial infarction according to cytochrome P450 2C19 genotype.
    Kim IS; Jeong YH; Park Y; Park KS; Yun SE; Park JR; Hwang SJ; Koh EH; Kwak CH; Hwang JY; Kim S
    JACC Cardiovasc Interv; 2011 Apr; 4(4):381-91. PubMed ID: 21511217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
    Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
    JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First analysis of the relation between CYP2C19 genotype and pharmacodynamics in patients treated with ticagrelor versus clopidogrel: the ONSET/OFFSET and RESPOND genotype studies.
    Tantry US; Bliden KP; Wei C; Storey RF; Armstrong M; Butler K; Gurbel PA
    Circ Cardiovasc Genet; 2010 Dec; 3(6):556-66. PubMed ID: 21079055
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Detection of clopidogrel resistance using ADP induced aggregometry with specific inhibitor PGE1.
    Slavik L; Ulehlova J; Krcova V; Hlusi A; Indrakova J; Hutyra M; Galuszka J; Indrak K
    Clin Lab; 2014; 60(9):1475-80. PubMed ID: 25291943
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prostaglandin E1 potentiates the effects of P2Y12 blockade on ADP-mediated platelet aggregation in vitro: Insights using short thromboelastography.
    Khanna V; Armstrong PC; Warner TD; Curzen N
    Platelets; 2015; 26(7):689-92. PubMed ID: 25734957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Post receptor determinants of acute platelet response to clopidogrel in patients with symptomatic myocardial ischemia.
    Nooney VB; Hurst NL; Chirkov YY; De Caterina R; Horowitz JD
    Vascul Pharmacol; 2015; 65-66():17-22. PubMed ID: 25460367
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytochrome 2C19 polymorphism and response to adjunctive cilostazol versus high maintenance-dose clopidogrel in patients undergoing percutaneous coronary intervention.
    Hwang SJ; Jeong YH; Kim IS; Park KS; Kang MK; Koh JS; Park JR; Park Y; Koh EH; Kwak CH; Hwang JY; Kim S
    Circ Cardiovasc Interv; 2010 Oct; 3(5):450-9. PubMed ID: 20823393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Does the VerifyNow P2Y12 assay overestimate "therapeutic response" to clopidogrel? Insights using short thrombelastography.
    Khanna V; Hobson A; Mikael R; Sambu N; Englyst N; Curzen N
    Thromb Haemost; 2014 Jun; 111(6):1150-9. PubMed ID: 24671606
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacodynamic effects of EV-077 in patients with diabetes mellitus and coronary artery disease on aspirin or clopidogrel monotherapy: results of an in vitro pilot investigation.
    Rollini F; Tello-Montoliu A; Patel R; Darlington A; Wilson RE; Franchi F; Muñiz-Lozano A; Desai B; Bender N; Sakariassen KS; Angiolillo DJ
    J Thromb Thrombolysis; 2014; 37(2):131-8. PubMed ID: 23943337
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential impact of cytochrome 2C9 allelic variants on clopidogrel-mediated platelet inhibition determined by five different platelet function tests.
    Gremmel T; Kopp CW; Seidinger D; Koppensteiner R; Panzer S; Sunder-Plassmann R; Mannhalter C; Steiner S
    Int J Cardiol; 2013 Jun; 166(1):126-31. PubMed ID: 22075408
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical efficacy of clopidogrel therapy.
    Shuldiner AR; O'Connell JR; Bliden KP; Gandhi A; Ryan K; Horenstein RB; Damcott CM; Pakyz R; Tantry US; Gibson Q; Pollin TI; Post W; Parsa A; Mitchell BD; Faraday N; Herzog W; Gurbel PA
    JAMA; 2009 Aug; 302(8):849-57. PubMed ID: 19706858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protease activated receptor-1 (PAR-1) mediated platelet aggregation is dependent on clopidogrel response.
    Kreutz RP; Breall JA; Kreutz Y; Owens J; Lu D; Bolad I; von der Lohe E; Sinha A; Flockhart DA
    Thromb Res; 2012 Aug; 130(2):198-202. PubMed ID: 22459907
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of unresponsiveness to aspirin and/or clopidogrel in patients with stable coronary heart disease.
    Lordkipanidzé M; Diodati JG; Schampaert E; Palisaitis DA; Pharand C
    Am J Cardiol; 2009 Nov; 104(9):1189-93. PubMed ID: 19840560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of the proton pump inhibitors and CYP2C19*2 polymorphism on platelet response to clopidogrel as assessed by four platelet function assays.
    Tsantes AE; Ikonomidis I; Papadakis I; Bonovas S; Gialeraki A; Kottaridi C; Kyriakou E; Kokori S; Douramani P; Kopterides P; Karakitsos P; Lekakis J; Kapsimali V
    Thromb Res; 2013 Aug; 132(2):e105-11. PubMed ID: 23830212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of cytochrome P450 2C19 and paraoxonase 1 polymorphisms on antiplatelet response to clopidogrel therapy in patients with coronary artery disease.
    Tresukosol D; Suktitipat B; Hunnangkul S; Kamkaew R; Poldee S; Tassaneetrithep B; Likidlilid A
    PLoS One; 2014; 9(10):e110188. PubMed ID: 25329996
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro.
    Weber AA; Reimann S; Schrör K
    Br J Pharmacol; 1999 Jan; 126(2):415-20. PubMed ID: 10077233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.